Listed by the USPTO as LARA, CAROLINE MONSERRAT
Tech Center 1600 • Art Units: 1633 1636 1651 1657 1658
This examiner grants 86% of resolved cases
LARA, CAROLINE MONSERRAT is associated with Tech Center 1600 and art unit 1633. The profile records 7 resolved cases and an allowance rate of 85.7%. The median time to allowance is 1099 days. Interviews correspond to a 16.7% lift in the allowance rate. The limited number of resolved cases makes the profile useful for background context, while reducing the basis for treating the figures as a broad forecast.
The listed companies are ModernaTX Inc., University of Florida Research Foundation Inc., and Wisconsin Alumni Research Foundation. The listed firms are BAUMGARTNER PATENT LAW, Casimir Jones, S.C., and EVENTIDE LAW LLC. These appearances identify organizations and counsel with experience in the docket. Practitioners can review their prosecution histories for issue-specific insight, while relying on the individual application record to make decisions about interviews, amendments, and timing.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18706176 | AAV-MEDIATED THERAPIES FOR VISION LOSS ASSOCIATED WITH FRIEDREICH’S ATAXIA | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18546145 | LNP COMPOSITIONS COMPRISING PAYLOADS FOR IN VIVO THERAPY | Final Rejection | ModernaTX, Inc. |
| 17925125 | RNA FORMULATIONS FOR HIGH VOLUME DISTRIBUTION, AND METHODS OF USING THE SAME FOR TREATING COVID-19 | Final Rejection | ModernaTX, Inc. |
| 17925114 | RNA FORMULATIONS FOR HIGH VOLUME DISTRIBUTION | Final Rejection | ModernaTX, Inc. |
| 18440260 | EFFICIENT DIFFERENTIATION OF SECOND HEART FIELD CARDIAC PROGENITOR CELLS AND RIGHT VENTRICLE CARDIOMYOCYTES FROM HUMAN PLURIPOTENT STEM CELLS | Non-Final OA | Wisconsin Alumni Research Foundation |
| 18763564 | HIGH-EFFICIENCY EXPRESSION VECTOR OF CIRCULAR RIBONUCLEIC ACID (circRNA) AND USE THEREOF | Non-Final OA | Zhejiang University |
| 18555508 | PACKAGING CELLS WITH TARGETED GENE KNOCKOUTS THAT IMPROVE RETROVIRAL VECTOR TITERS | Non-Final OA | The Regents of the University of California |
| 18528348 | GENERATING QUIESCENT HEPATIC STELLATE CELLS AND THEIR USE IN LIVER MODELS | Non-Final OA | The Cleveland Clinic Foundation |
| 18842083 | PROCESS TO ENHANCE VIRAL VECTOR PRODUCTION IN CELL-CULTURE USING GLYCYL-GLUTAMINE | Non-Final OA | Evonik Operations GmbH |
| 18549887 | SYSTEMS, METHODS, AND COMPOSITIONS FOR ALTERING THE EXPRESSION OF ENDOGENOUS CIRCULAR RNAS | Non-Final OA | UNM Rainforest Innovations |
| 18841883 | ENGINEERED IMMUNOMODULATORY ACCESSORY CELLS IMPROVE ALLOGENEIC ISLET TRANSPLANTATION WITHOUT IMMUNOSUPPRESSION | Non-Final OA | CORNELL UNIVERSITY |
| 18184568 | PERSISTENT HSV GENE DELIVERY SYSTEM | Non-Final OA | University of Houston System |
| 18696121 | METHOD FOR PRODUCING CELL HAVING DNA DELETION SPECIFIC TO ONE OF HOMOLOGOUS CHROMOSOMES | Non-Final OA | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy85.7% of resolved applications examined by Caroline Monserrat Lara were allowed (7 resolved cases), compared with 34.8% across Art Unit 1633 over the last five years.
This examiner's interview lift is +16.7 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Caroline Monserrat Lara took 1,099 days on average from filing to allowance.
Caroline Monserrat Lara examines applications in Art Unit 1633 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
